138 related articles for article (PubMed ID: 38836510)
1. Safety profile of proprotein convertase subtilisin/kexin type 9 inhibitors alirocumab and evolocumab: an updated meta-analysis and meta-regression.
Rivera FB; Cha SW; Magalong JV; Bantayan NRB; Cruz LLA; Arias-Aguirre E; Aguirre Z; Varona MC; Co EMF; Lumbang GNO; Enkhmaa B
Curr Med Res Opin; 2024 Jul; 40(7):1103-1121. PubMed ID: 38836510
[TBL] [Abstract][Full Text] [Related]
2. Systematic Review and Network Meta-Analysis on the Efficacy of Evolocumab and Other Therapies for the Management of Lipid Levels in Hyperlipidemia.
Toth PP; Worthy G; Gandra SR; Sattar N; Bray S; Cheng LI; Bridges I; Worth GM; Dent R; Forbes CA; Deshpande S; Ross J; Kleijnen J; Stroes ESG
J Am Heart Assoc; 2017 Oct; 6(10):. PubMed ID: 28971955
[TBL] [Abstract][Full Text] [Related]
3. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
4. An Updated Meta-Analysis for Safety Evaluation of Alirocumab and Evolocumab as PCSK9 Inhibitors.
Choi HD; Kim JH
Cardiovasc Ther; 2023; 2023():7362551. PubMed ID: 36704607
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein Apheresis and Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors in Patients With Heterozygous Familial Hypercholesterolemia: A One Center Study.
Kolovou V; Katsiki N; Makrygiannis S; Mavrogieni S; Karampetsou N; Manolis A; Melidonis A; Mikhailidis DP; Kolovou GD
J Cardiovasc Pharmacol Ther; 2021 Jan; 26(1):51-58. PubMed ID: 32729335
[TBL] [Abstract][Full Text] [Related]
6. A Systematic Review of PCSK9 Inhibitors Alirocumab and Evolocumab.
McDonagh M; Peterson K; Holzhammer B; Fazio S
J Manag Care Spec Pharm; 2016 Jun; 22(6):641-653q. PubMed ID: 27231792
[TBL] [Abstract][Full Text] [Related]
7. Proprotein convertase subtilisn/kexin type 9 inhibitors and small interfering RNA therapy for cardiovascular risk reduction: A systematic review and meta-analysis.
Imran TF; Khan AA; Has P; Jacobson A; Bogin S; Khalid M; Khan A; Kim S; Erqou S; Choudhary G; Aspry K; Wu WC
PLoS One; 2023; 18(12):e0295359. PubMed ID: 38055686
[TBL] [Abstract][Full Text] [Related]
8. Safety of Proprotein Convertase Subtilisin/Kexin Type 9 Monoclonal Antibodies in Regard to Diabetes Mellitus: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
Chen Q; Wu G; Li C; Qin X; Liu R; Zhang M
Am J Cardiovasc Drugs; 2020 Aug; 20(4):343-353. PubMed ID: 31823301
[TBL] [Abstract][Full Text] [Related]
9. Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors and Ezetimibe on Risk of New-Onset Diabetes: A Systematic Review and Meta-Analysis of Large, Double-Blinded Randomized Controlled Trials.
Chiu SW; Pratt CM; Feinn R; Chatterjee S
J Cardiovasc Pharmacol Ther; 2020 Sep; 25(5):409-417. PubMed ID: 32419478
[TBL] [Abstract][Full Text] [Related]
10. Indirect comparison of the efficacy and safety of alirocumab and evolocumab: a systematic review and network meta-analysis.
Guedeney P; Sorrentino S; Giustino G; Chapelle C; Laporte S; Claessen BE; Ollier E; Camaj A; Kalkman DN; Vogel B; De Rosa S; Indolfi C; Lattuca B; Zeitouni M; Kerneis M; Silvain J; Collet JP; Mehran R; Montalescot G
Eur Heart J Cardiovasc Pharmacother; 2021 May; 7(3):225-235. PubMed ID: 32275743
[TBL] [Abstract][Full Text] [Related]
11. The efficacy of PCSK9 inhibitors on major cardiovascular events and lipid profile in patients with diabetes: a systematic review and meta-analysis of randomized controlled trials.
Imbalzano E; Ilardi F; Orlando L; Pintaudi B; Savarese G; Rosano G
Eur Heart J Cardiovasc Pharmacother; 2023 Jun; 9(4):318-327. PubMed ID: 36972610
[TBL] [Abstract][Full Text] [Related]
12. Efficacy and Safety of PCSK9 Monoclonal Antibodies in Patients at High Cardiovascular Risk: An Updated Systematic Review and Meta-Analysis of 32 Randomized Controlled Trials.
Mu G; Xiang Q; Zhou S; Liu Z; Qi L; Jiang J; Gong Y; Xie Q; Wang Z; Zhang H; Huo Y; Cui Y
Adv Ther; 2020 Apr; 37(4):1496-1521. PubMed ID: 32108309
[TBL] [Abstract][Full Text] [Related]
13. Additive effects of ezetimibe, evolocumab, and alirocumab on plaque burden and lipid content as assessed by intravascular ultrasound: A PRISMA-compliant meta-analysis.
Liang D; Li C; Tu Y; Li Z; Zhang M
Medicine (Baltimore); 2022 Oct; 101(41):e31199. PubMed ID: 36254013
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of injectable PCSK9 inhibitors in dyslipidaemias' treatment and cardiovascular disease prevention: An overview of 86 systematic reviews and a network metaanalysis.
Pamporis K; Karakasis P; Simantiris S; Sagris M; Bougioukas KI; Fragakis N; Tousoulis D
Clin Investig Arterioscler; 2024; 36(2):86-100. PubMed ID: 38040529
[TBL] [Abstract][Full Text] [Related]
15. Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression.
Hirsh Raccah B; Yanovsky A; Treves N; Rotshild V; Renoux C; Danenberg H; Eliaz R; Matok I
Int J Cardiol; 2021 Jul; 335():7-14. PubMed ID: 33892045
[TBL] [Abstract][Full Text] [Related]
16. Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial.
Sabatine MS; Leiter LA; Wiviott SD; Giugliano RP; Deedwania P; De Ferrari GM; Murphy SA; Kuder JF; Gouni-Berthold I; Lewis BS; Handelsman Y; Pineda AL; Honarpour N; Keech AC; Sever PS; Pedersen TR
Lancet Diabetes Endocrinol; 2017 Dec; 5(12):941-950. PubMed ID: 28927706
[TBL] [Abstract][Full Text] [Related]
17. PCSK9 inhibitors revisited: Effectiveness and safety of PCSK9 inhibitors in a real-life Spanish cohort.
Vicente-Valor J; García-González X; Ibáñez-García S; Durán-García ME; de Lorenzo-Pinto A; Rodríguez-González C; Méndez-Fernández I; Percovich-Hualpa JC; Herranz-Alonso A; Sanjurjo-Sáez M
Biomed Pharmacother; 2022 Feb; 146():112519. PubMed ID: 34968928
[TBL] [Abstract][Full Text] [Related]
18. Alirocumab therapy in individuals with type 2 diabetes mellitus and atherosclerotic cardiovascular disease: analysis of the ODYSSEY DM-DYSLIPIDEMIA and DM-INSULIN studies.
Ray KK; Del Prato S; Müller-Wieland D; Cariou B; Colhoun HM; Tinahones FJ; Domenger C; Letierce A; Mandel J; Samuel R; Bujas-Bobanovic M; Leiter LA
Cardiovasc Diabetol; 2019 Nov; 18(1):149. PubMed ID: 31706300
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.
Guedeney P; Giustino G; Sorrentino S; Claessen BE; Camaj A; Kalkman DN; Vogel B; Sartori S; De Rosa S; Baber U; Indolfi C; Montalescot G; Dangas GD; Rosenson RS; Pocock SJ; Mehran R
Eur Heart J; 2022 Feb; 43(7):e17-e25. PubMed ID: 31270529
[TBL] [Abstract][Full Text] [Related]
20. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
